Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates

Abstract

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

1 - 18 . (canceled) 
     
     
         19 . An immunogenic composition comprising a polysaccharide-carrier protein conjugate and a pharmaceutically acceptable carrier, wherein the polysaccharide of the polysaccharide-carrier protein conjugate comprises an  S.   pneumoniae  serotype 23B polysaccharide repeating unit of the following structure: 
       
         
           
           
               
               
           
         
       
       wherein the carrier protein is CRM197; wherein the polysaccharide-carrier protein conjugate has a molecular weight from 1,000 kDa to 10,000 kDa; and further wherein the polysaccharide-carrier protein conjugate has a polysaccharide to carrier protein mass ratio from 0.5 to 2.0. 
     
     
         20 . The immunogenic composition of  claim 19 , further comprising one or more additional polysaccharide-carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide of a particular  S.   pneumoniae  serotype conjugated to CRM197, and wherein the  S.   pneumoniae  serotypes are selected from the group consisting of: 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7B, 7C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 17F, 18C, 19A, 19F, 20, 21, 22A, 22F, 23A, 23F, 24F, 27, 28A, 31, 33F, 34, 35A, 35B, 35F, and 38 . 
     
     
         21 . The immunogenic composition of  claim 20 , wherein the one or more additional polysaccharide-carrier protein conjugates comprises a polysaccharide of S.  pneumoniae  serotype 23A. 
     
     
         22 . The immunogenic composition of  claim 20 , wherein the one or more additional polysaccharide-carrier protein conjugates comprises a polysaccharide of  S.   pneumoniae  serotype 23F. 
     
     
         23 . The immunogenic composition of  claim 20 , wherein the immunogenic composition is formulated to comprise 0.4 to 4 µg/mL of each polysaccharide present, except for serotype 6B polysaccharide which, if present, comprises 0.8 to 8 µg/mL of polysaccharide; and CRM197 carrier protein in an amount from about 0.5x to 3x the total amount of polysaccharide. 
     
     
         24 . The immunogenic composition of  claim 23 , further comprising wherein the immunogenic composition is formulated to further comprise 150 mM sodium chloride, 20 mM L-histidine buffer, and 0.05 to 2% w/v surfactant. 
     
     
         25 . The immunogenic composition of  claim 24 , further comprising an adjuvant. 
     
     
         26 . The immunogenic composition of  claim 25 , wherein the adjuvant is an aluminum-based adjuvant. 
     
     
         27 . The immunogenic composition of  claim 26 , wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate, and aluminum hydroxide. 
     
     
         28 . The immunogenic composition of  claim 27 , wherein the adjuvant is aluminum phosphate. 
     
     
         29 - 32 . (canceled) 
     
     
         33 . A method of preventing a  Steptococcus   pneumoniae  infection, disease or condition associated with serotype 23F  S.   pneumoniae  in a subject, the method comprising the step of administering a prophylactically effective amount of an immunogenic composition of  claim 21 . 
     
     
         34 . A method of preventing a  Steptococcus   pneumoniae  infection, disease or condition associated with serotype 23A  S.   pneumoniae  in a subject, the method comprising the step of administering a prophylactically effective amount of an immunogenic composition of  claim 22 . 
     
     
         35 . The immunogenic composition of  claim 19 , wherein the 23B polysaccharide repeating unit is conjugated at the 2 nd  or 3 rd  carbon position of β-Glcp or β-Rhap. 
     
     
         36 . The immunogenic composition of  claim 19 , wherein at least 90% of the 23B polysaccharide repeating units are conjugated at the 2 nd  or 3 rd  carbon position of β-Rhap. 
     
     
         37 . The immunogenic composition of  claim 19 , wherein the degree of conjugation of the conjugate is between 3-13. 
     
     
         38 . The immunogenic composition of  claim 19 , wherein the polysaccharide has a molecular weight of between 50 kDa and 1,000 kDa. 
     
     
         39 . The immunogenic composition of  claim 19 , wherein the polysaccharide has a molecular weight of between 100 kDa and 300 kDa. 
     
     
         40 . The immunogenic composition of  claim 19 , wherein the polysaccharide-carrier protein conjugate has a polysaccharide to carrier protein mass ratio from 0.5 to 1.5. 
     
     
         41 . The immunogenic composition of  claim 19 , wherein the polysaccharide-carrier protein conjugate has a polysaccharide to carrier protein mass ratio from 0.8 to 1.2. 
     
     
         42 . The immunogenic composition of  claim 19 , wherein the immunogenic composition comprises less than about 25% of non-covalently associated polysaccharide compared to the total amount of polysaccharide. 
     
     
         43 . The immunogenic composition of  claim 19 , wherein the immunogenic composition comprises less than about 15% of non-covalently associated polysaccharide compared to the total amount of polysaccharide. 
     
     
         44 . The immunogenic composition of  claim 19 , wherein at least 90% of the 23B polysaccharide repeating units are conjugated at the 2 nd  or 3 rd  carbon position of β-Rhap; wherein the degree of conjugation of the conjugate is between 3-13; wherein the polysaccharide has a molecular weight of between 100 kDa and 300 kDa; wherein the mass ratio of polysaccharide to carrier protein in the conjugate is between 0.8 and 1.2; and wherein the polysaccharide-carrier protein conjugate comprises less than about 15% of non-covalently associated polysaccharide compared to the total amount of polysaccharide.